Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel

FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.